RICHD Stock Overview

A pharmaceutical company, develops and manufactures pharmaceutical products. More details

RICHD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (8.2x) is below the AR market (23.3x)

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

Shares are highly illiquid

Large one-off items impacting financial results

My Notes

Capture your thoughts, links and company narrative

Laboratorios Richmond S.A.C.I.F. Competitors

Instituto Rosenbusch

BASE:ROSE

AR$5.0b

Lavipharm

ATSE:LAVI

€137.3m

Nang Kuang Pharmaceutical

TWSE:1752

NT$4.2b

Kotra Industries Berhad

KLSE:KOTRA

RM 658.5m

Price History & Performance

Summary of share price highs, lows and changes for Laboratorios RichmondC.I.F
Historical stock prices
Current Share Price	AR$0.75
52 Week High	AR$0.75
52 Week Low	AR$0.75
Beta	-0.099
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	RICHD	AR Pharmaceuticals	AR Market
7D	0%	-0.8%	4.8%
1Y	n/a	-27.8%	131.9%

Return vs Industry: Insufficient data to determine how RICHD performed against the AR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how RICHD performed against the AR Market.

Price Volatility

Is RICHD's price volatile compared to industry and market?
RICHD volatility
RICHD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	6.2%
10% most volatile stocks in AR Market	9.2%
10% least volatile stocks in AR Market	5.0%

Stable Share Price: RICHD's share price has been volatile over the past 3 months compared to the AR market.

Volatility Over Time: Insufficient data to determine RICHD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1935	620	Juan Manuel Artola	www.richmondlab.com

Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company sells its products in Latin America, Africa, Asia, and the Middle East.

Laboratorios Richmond S.A.C.I.F. Fundamentals Summary

How do Laboratorios RichmondC.I.F's earnings and revenue compare to its market cap?
RICHD fundamental statistics
Market cap	US$137.85m
Earnings (TTM)	US$16.79m
Revenue (TTM)	US$36.73m

8.2x

P/E Ratio

3.8x

P/S Ratio

Is RICHD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RICHD income statement (TTM)
Revenue	AR$37.55b
Cost of Revenue	AR$11.93b
Gross Profit	AR$25.62b
Other Expenses	AR$8.45b
Earnings	AR$17.17b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	212.60
Gross Margin	68.23%
Net Profit Margin	45.73%
Debt/Equity Ratio	223.8%

How did RICHD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 05:32
End of Day Share Price	2024/09/25 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Laboratorios Richmond S.A.C.I.F. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Laboratorios RichmondC.I.F BASE:RICHD Stock Report